Another terrific post. It is becoming clear Brilacidin may prove to be a superior drug to Remdesivir .
IMO Clinical trials should be expected to show Brilacidin will effectively reduce viral load. Its invitro studies have shown:
1.its virucidal ability will kill the virus on contact
;2 it will prevent viral entry by blocking the S spike protein from attaching to the ACE protein receptor
3 it will prevent infected cells from producing new virus by interfering with the M protein,protease
The selectivity index was increased by a multiple of 2 today by the finding that the dose of Brilacidin could be cut in half and it was still effective. Previous in vitro tests have shown no toxicity. The SI will increase as the higher doses are required to produce toxicity and lower doses are shown to be effective. My prediction is Brilacidin will have the highest SI shown against Covid 19.
The above coupled with Brilacidin's long half liife and superior pharmacokinetics will swiftly reduce viral loads to reduce other complications. Its anti inflammatory abilities will be an aid to severely ill Covid 19 patients by reducing inflammatory complications which lead to pulmonary failure and death.Its broad spectrum antibiotic qualities will prevent secondary infections.
IMO Brilacidin should accomplish several end points that Remdesivir has been unable to conclusively accomplish in any trial. Brilacidin should lower the mortality in severely ill patients and should reduce complications in moderately ill patients. It should reduce the long term inflammatory complications such as the pediatric Kawasaki like illness. It may prevent illness in newly infected patients at high risk for progression to severe illness.
Brilacidin is much safer than Remdesivir. Remdesivir was given to normal volunteers as a part of the Ebola trials and its effects were barely reported by Gilead. Brilacidin was shown to be safe as well as effective in its ABSSSI trial with virtually no complications at the dose used in the 2b trial{ it seems as if the Covid trials will be done at a lower dose}. Brilacidin's safety will make it an ideal addition to combination treatments.
Of course much of the above needs to be confirmed in the human clinical trials, but if you review the PR's from the first Covid 19 for Brilacidin report on 2/18/2020 you will see not only a progression of the science but a confidence in the drug which has led the researchers to plan 2 separate peer review publications, sponsor the drug for funding and promote Brilacidin for other serious viral disorders without known treatments such as MERS,SARS and Encephalitis.
IMO the upcoming clinical trials will confirm Brilacidin's promise. Today's PR was very good news for future Covid 19 patients.
GLTA Farrell
c
IMO Clinical trials should be expected to show Brilacidin will effectively reduce viral load. Its invitro studies have shown:
1.its virucidal ability will kill the virus on contact
;2 it will prevent viral entry by blocking the S spike protein from attaching to the ACE protein receptor
3 it will prevent infected cells from producing new virus by interfering with the M protein,protease
The selectivity index was increased by a multiple of 2 today by the finding that the dose of Brilacidin could be cut in half and it was still effective. Previous in vitro tests have shown no toxicity. The SI will increase as the higher doses are required to produce toxicity and lower doses are shown to be effective. My prediction is Brilacidin will have the highest SI shown against Covid 19.
The above coupled with Brilacidin's long half liife and superior pharmacokinetics will swiftly reduce viral loads to reduce other complications. Its anti inflammatory abilities will be an aid to severely ill Covid 19 patients by reducing inflammatory complications which lead to pulmonary failure and death.Its broad spectrum antibiotic qualities will prevent secondary infections.
IMO Brilacidin should accomplish several end points that Remdesivir has been unable to conclusively accomplish in any trial. Brilacidin should lower the mortality in severely ill patients and should reduce complications in moderately ill patients. It should reduce the long term inflammatory complications such as the pediatric Kawasaki like illness. It may prevent illness in newly infected patients at high risk for progression to severe illness.
Brilacidin is much safer than Remdesivir. Remdesivir was given to normal volunteers as a part of the Ebola trials and its effects were barely reported by Gilead. Brilacidin was shown to be safe as well as effective in its ABSSSI trial with virtually no complications at the dose used in the 2b trial{ it seems as if the Covid trials will be done at a lower dose}. Brilacidin's safety will make it an ideal addition to combination treatments.
Of course much of the above needs to be confirmed in the human clinical trials, but if you review the PR's from the first Covid 19 for Brilacidin report on 2/18/2020 you will see not only a progression of the science but a confidence in the drug which has led the researchers to plan 2 separate peer review publications, sponsor the drug for funding and promote Brilacidin for other serious viral disorders without known treatments such as MERS,SARS and Encephalitis.
IMO the upcoming clinical trials will confirm Brilacidin's promise. Today's PR was very good news for future Covid 19 patients.
GLTA Farrell
c
8
